Neurotoxizität von 5-Fluorouracil

Literatur

• 1 Akiba T, Okeda R, Tajima T. Metabolites of 5-fluorouracil, α-fluoro-β-alanine and fluoroacetic acid, directly injure myelinated fibers in tissue culture.  Acta Neuropathol. 1996;  92 8-13
• 2 Aksoy M, Basu T K, Brient J, Dickerson J WT. Thiamine status of patients treated with drug combinations containing 5-fluorouracil.  Eur J Cancer. 1980;  16 1041-1045
• 3 Boileau G, Piro A J, Lahiri S R. et al . Cerebellar ataxia during 5-fluorouracil (NSC-19 893) therapy.  Cancer Chemother Rep. 1971;  55 595-598
• 4 Bourke R S, West C R, Chheda G. et al . Kinetics of entry and distribution of 5-fluorouracil in cerebrospinal fluid following intravenous injection in a primate.  Cancer Res. 1973;  33 1735
• 5 Bygrave H A, Geh J I, Jani Y, Glynne-Jones R. Neurological complications of 5-fluorouracil chemotherapy: case report and review of the literature.  Clin Oncol. 1998;  10 334-336
• 6 Diasio R B. The role of dihydropyrimidine dehydrogenase (DPD) modulation in 5-FU pharmacology.  Oncology. 1998;  12 23-27
• 7 Diasio R B, Beavers T L, Carpenter J T. Familial deficiency of dihydropyrimidine dehydrogenase.  J Clin Invest. 1988;  81 47-51
• 8 Diasio R B, Harris B E. Clinical pharmacology of 5-fluorouracil.  Clin Pharmacogenetics. 1989;  16 215-237
• 9 Etienne M C, Lagrange J L, Dassonville O. et al . Population study of dihydropyrimidine dehydrogenase in cancer patients.  J Clin Oncol. 1994;  12 2248-2253
• 10 Fassas A BT, Gattani A M, Morgello S. Cerebral demyelination with 5-fluorouracil and levamisole.  Cancer Invest. 1994;  12 379-383
• 11 Fleming R A, Milano G, Thyss A. et al . Correlation between dihydropyrimidine dehydrogenase activity in peripheral mononuclear cells and systemic clearance of fluorouracil in cancer patients.  Cancer. 1992;  52 2899-2902
• 12 Gottlieb J A, Luce J K. Cerebellar ataxia with weekly 5-fluorouracil administration (letter).  Lancet. 1971;  i 138-139
• 13 Greenwald E S. Organic mental changes with fluorouracil therapy.  J Am Med Assoc. 1976;  235 248-249
• 14 Grem J L. 5-Fluoropyrimidines. 2nd ed Philadelphia: Lippinscott-Raven In: Chabner BA, Longo DL (eds.), Cancer chemotherapy and biotherapy: principles and practice 1996: 149-211
• 15 Harris B E, Carpenter J T, Diasio R B. Severe 5-fluorouracil toxicity secondary to dihydropyrimidine dehydrogenase deficiency. A potentially more common pharmacogenetic syndrome.  Cancer. 1991;  68 499-501
• 16 Hook C C, Kimmel D W, Kvols L K. et al . Multifocal inflammatory leukencephalopathy with 5-fluorouracil and levamisol.  Ann Neurol. 1992;  31 262-267
• 17 Kliche K O, Schalhorn A, Höffken K. Nachweis von DPD-Exon-14-Skipping vor 5-Fluorouracil-Behandlung?.  Dtsch Med Wochenschr. 2002;  127 463-464
• 18 Koenig H, Patel A. Biochemical basis for fluorouracil neurotoxicity.  Arch Neurol. 1970;  23 155-160
• 19 Leichman L, Brown T, Poplin B. Symptomatic, radiologic, and pathologic changes in the central nervous system (CNS) associated with 5-fluorouracil (5-FU) and levamisole (LEV) therapy (abstract).  Proc Am Soc Clin Oncol. 1993;  12 198
• 20 Luppi G, Zoboli A, Barbieri F, Crisi G, Piccinini L, Silingardi V. Multifocal leukencephalopathy associated with 5-fluorouracil and levamisole adjuvant therapy for colon cancer. A report of two cases and review of the literature.  Ann Oncol. 1996;  7 412-415
• 21 Mehta V K, Poen J C, Ford J M. et al . Protracted venous infusion 5-fluorouracil with concomitant radiotherapy compared with bolus 5-fluorouracil for unresectable pancreatic cancer.  Am J Clin Oncol. 2001;  24 155-159
• 22 Meropol N J, Creaven P J, Petrelli N J. et al . Seizures associated with leucovorin administration in cancer patients.  JNCI. 1995;  87 56-58
• 23 Milano G, Etienne M C. Fluorinated pyrimidines 289 - 300;. Baltimore, Williams & Wilkins in Grochow LB, Ames MM (eds): clinician’s guide to chemotherapy pharmacokinetics and pharmacodynamics 1998
• 24 Milano G, Etienne M C, Pierrefite V, Barberi-Heyob M, Deporte-Fety R, Renee N. Dihydropyrimidine dehydrogenase deficiency and fluorouracil-related toxicity.  Br J Cancer. 1999;  79 627-630
• 25 Milano G, McLeod H L. Can dihydropyrimidine dehydrogenase impact 5-fluorouracil-based treatment?.  Eur J Cancer. 2000;  36 37-42
• 26 Moertel C G, Reitmeir R J, Bolton C F. et al . Cerebellar ataxia associated with fluorinated pyrimidine therapy.  Cancer Chemother Rep. 1964;  41 15-18
• 27 Ridge S A, Sludden J, Wei X. et al . Dihydropyridine dehydrogenase pharmacogenetics in patients with colorectal cancer.  Br J Cancer. 1998;  77 497-500
• 28 Riehl J L, Brown W J. Acute cerebellar syndrome secondary to 5-fluorouracil therapy.  Neurology. 1964;  14 254
• 29 Saletti P, Pagani O, Sessa C, Goldhirsch A. Two cases of neurotoxicity possibly related to 5-fluorouracil and FA administration.  Ann Oncol. 1996;  7 2
• 30 Sloan J A, Goldberg R M, Sargent D J. et al . Women experience greater toxicity with fluorouracil-based chemotherapy for colorectal cancer.  J Clin Oncol. 2002;  20 1491-1498
• 31 Soukop M, Kalman K C. Thiamine status in cancer patients and the effect of 5-fluorouracil therapy (abstract).  Br J Cancer. 1978;  38 180
• 32 Sucker C, Scheffold N, Cyran J. Koronarer Vasospasmus unter Chemotherapie mit 5-Fluorouracil.  Dtsch Med Wochenschr. 2001;  46 1300
• 33 Wei X, McLeod H L, McMurrough J. et al . Molecular basis of the human dihydropyrimidine dehydrogenase deficiency and 5-fluorouracil toxicity.  J Clin Invest. 1996;  98 610-615
• 34 Yeh K H, Cheng A L. Acute confusion induced by high-dose infusion of 5-fluorouracil and folinic acid.  J Formos Med Assoc. 1994;  93 721-723